In vitro and in vivo characterization of a reversible synthetic heparin analog.

ABSTRACT:

Background

The global supply of unfractionated heparin (UFH) and all commercially available low molecular weight heparins (LMWH) remain dependent on animal sources, such as porcine intestine or bovine lung. Recent experience has shown that contamination of the supply chain (with over-sulfated chondroitin sulfates) can result in lethal toxicity. Fondaparinux is currently the only commercially available synthetic analog of heparin. We recently described a new class of chemoenzymatically synthesized heparin analogs. One of these compounds (S12-mer) is a dodecasaccharide consisting of an antithrombin-binding moiety with repeating units of IdoA2S-GlcNS6S and two 3-O-sulfate groups that confer the ability to bind protamine.

Objective/methods

We sought to further characterize this

SUBMITTER: Whelihan MF 

PROVIDER: S-EPMC4751072 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature